Drug Deals Tie Prices to How Well Patients Do
According to New York Times -
"In a deal expected to be announced Thursday, Merck
has agreed to peg what the insurer Cigna
pays for the diabetes
drugs Januvia and Janumet to how well Type
2 diabetes patients are able to control their blood sugar. "
An interesting concept that has been tried in other countries. Is this the way to go? Could this initiate the effective top down directive that permeates the corporate culture or just another gimmick to bolster sales?
If this practice became common place what might it mean to the pharmaceutical landscape?